All News

Big data forecast to revolutionise pharma’s operations, everything from outsourcing thorough to drug discovery.

China and India tipped to become the highest revenue-generating emerging market for generic drug manufacturers in the next 5 years.

Gavi allows freezing of oocytes and embryos at key stages, whereas Geri medium supports undisturbed embryo growth.

Opadry QX is a new tablet film coating, designed to meet the manufacturing flexibility, batch consistency and efficiencies.

HPAPI growth driven by virtual and mid-sized pharma, with biosimilars expanding rapidly in Europe.

We are pleased to announce that Our facility of (Haryana) India, was inspected by US-FDA and is successfully approved.

The CDMO will specialise in delivering API development and manufacturing solutions.

As part of the serialisation roll-out, the CDMO has developed a unique pricing model which spreads the cost of the process across each customer’s ongoing supply agreement, removing the need to make any upfront investment.

Company to expand its activities in R&D/QC testing, and to offer new analytical services to clients.

Adds speed and flexibility for small-scale API production.

MEDI2070 is in development as a next-generation IL-23-only targeted therapy for Crohn's disease and ulcerative colitis.

Cosentyx significantly superior to Stelara in delivering long-lasting skin clearance in psoriasis over 52 weeks.

NIH-funded mouse study identifies a key player in the progression of the disorder.

Assemblies save up to 60% on processing time and offer a safe approach to ultrafiltration of biologics and vaccines.

James O’Brien will lead the company's manufacturing execution system business to its next phase of growth.

Will enable manufacturers to reduce costs by eliminating cleaning and validation requirements, as well as hardware infrastructure.

The reductions are expected to affect R&D units and headquarter staff functions.

New site expands the company's global operations for small molecule and biologics manufacturing, and marks the company's first manufacturing presence in Asia.

New long-term collaboration to develop next generation oncolytic virus platform and lead candidate VSV-GP.

The company will exhibit and demonstrate a range of instruments and consumables from the liquid handling portfolio, including: pipettes & tips, manual and electronic dispensers and automated pipetting systems.

Providing value added development services will allow participants to edge out competition, finds Frost & Sullivan's Transformational Health team.

Main drivers of this substantial growth include medical tourism, a lack of strict price regulation, a rising disease burden, and a lack of dependence on imported branded products.

The introduction of a single vial presentation was part of commitments required by the FDA when it approved Egrifta (Tesamorelin for Injection).

The HMI 4.0 is suited for both stand-alone machines and entire lines and provides an interface for data collection, data sharing and visualization

Submission of Marketing Authorization Application to the EMA planned in the coming weeks.

The technology controls the freezing stage of the freeze drying process for more consistent and repeatable outcomes that aid drug development, scale-up and production efforts.

The new laboratories will enable pharmaceutical companies to test various topical and transdermal formulations for both new and existing drugs.

Removes protein aggregates and other impurities in high pH and high conductivity mAb feed streams.

Continuous processing at a ‘tipping point’, with CDMO implementation over next 3 years, but the industry needs a better definition of what ‘continuous’ means.

Acquisition of PharmaCore’s portfolio also complements Cambrex's existing large-scale, multi-purpose manufacturing facilities in the US and Europe.

Company to continue to operate as one company with two distinct and complementary businesses to retain operating strength and financial flexibility.

Funds will be used for Phase II development and manufacturing.

Innovative excipients for controlled release including, new biodegradable, biocompatible polymers for sustained release injectables and Parteck SRP 80 for oral solid formulation.

Amjevita is the first adalimumab biosimilar approved by the FDA and has been approved for the treatment of seven inflammatory diseases.

Comprehensive roadmap lays out key commitments the pharmaceutical companies pledge to deliver by 2020 to reduce antimicrobial resistance.

Jeremy Drummond will focus on growing the CDMO’s API and finished dosage form development and manufacturing business in Europe and North America.

Ilaris is the first and only US FDA-approved biologic treatment for patients with TRAPS, HIDS/MKD and FMF disease.

Alliance will be extended to include Dow’s advanced technology-based pharmaceutical excipients.

50 years’ experience in manufacturing Polysorbates, Sorbitan Esters, and other non-ionic surfactants allows Kolb to steer this complex molecular diversity. Let’s talk about our new Hedisan product portfolio and its unique philosophy at CPHI Worldwide 2...

Freeze-dried cellular components can be rehydrated to churn out useful proteins.

Fully integrated site from raw material to API, formulation, filling and finish.

Results published in the New England Journal of Medicine demonstrate that KAF156 shows activity against blood and liver stages of malaria parasites, including artemisinin-resistant parasites.

Viventia’s Lead Product Candidate, ViciniumTM, being developed for high-grade non-muscle invasive bladder cancer, with topline Phase 3 data expected in 1H 2018.

Company also in the process of setting up a training collaboration with National Institute for Bioprocessing Research and Training (NIBRT) to develop skills for Ireland’s biologics sector, training 1,500 professionals per year.

Innovative Twin system with two 3,000-L bioreactors and associated downstream processing equipment put into operation. Second significant expansion in one year.

Focus on Merck’s brands Glucophage, Concor and Euthyrox to meet increasing patient needs in the areas of diabetes, cardiovascular diseases and thyroid disorders.

Extends the current indications for Opdivo to include the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy.

Acquisition expands global GI R&D pipeline and takes a leading R&D position in NASH

Combination provides an enterprise platform for comprehensive data management, analysis and compound design in drug discovery.

New 24-page guide that brings together applications, protocols, results and citations for researchers.

Gene-regulating RNA molecules could help treat early-stage breast cancer tumours before they spread.

Current R&D strategies in osteoarthritis are characterized by a trend towards developing new analgesics with novel MOAs, and drugs with disease-modifying effects.

Unique antibody purification system compatible with any conjugation technology.

Creates 40 R&D jobs and grows total to 120 new roles at new site.

Approval given to EXONDYS 51 (eteplirsen) as a once weekly intravenous infusion of 30 mg/kg for the treatment of DMD in patients who have a confirmed mutation in the DMD gene that is amenable to exon 51 skipping.

Adds first-in-class technology to company's innovative eye care pipeline.

Shire to consider appeal.

Glyxambi is a single tablet that combines Jardiance and Trajenta and has been shown to improve blood sugar control in adults with type 2 diabetes.

This was the first clinical trial to combine these two different anti-diabetes medicines, a GLP-1 receptor agonist and an SGLT-2 inhibitor, as an addition to standard-of-care therapy to evaluate potential benefits for patients with type 2 diabetes with...

ZIm has developed a new novel drug delivery system " Orally Disintegrating Strips" to provide patient convenience & adherance.

Administering drugs to paediatric, geriatric, dysphagic and mentally challenged patients has always been a challenge...

Helsinn Advanced Synthesis develops and manufactures compounds for clinical and commercial use in several containment classes: Active Pharmaceutical Ingredients (APIs), Advanced Intermediates, High Potency APIs (HPAPIs) and Anticancer compounds. These ...

Alessandro Maselli is to become its new Senior Vice President of Global Operations, and Christine Dolan will assume the role of Senior Vice President of Global Product Development.

Focus on issues in modern tablet production and how elements including punch and die design, tooling specification and aftercare can affect the end product.

Company expects to start submitting regulatory applications for the candidate vaccine for the prevention of shingles in people 50 years and above later this year.

MIT chemists have now shown they can package three or more drugs into a novel type of nanoparticle, allowing them to design custom combination therapies for cancer.

782 products currently in the ophthalmology therapy pipeline.

Vitae Pharmaceuticals acquired for a total transaction value of approximately $639 million.

Five year project will create more cost-effective purification program.

Mugard is a medical device for the prevention and management of the signs and symptoms of oral mucositis caused by chemotherapy and radiation therapy.

Acquisition adds expanded drug development services and spray drying technology.

The Korean biosimilar market was another area that gathered much international interest at CPHI Korea.

The data support the company's phage cocktails products' great potential as effective therapies to treat antibiotic resistant and difficult-to-treat infections.

This agreement allows any organisation, through CPI or NIBRT, to access Horizon’s biomanufacturing cell lines for research purposes.

The combination of the two businesses allows Lonza to offer InterHealth’s more than 15 branded ingredients, including its cornerstone ingredient, UC-II, which is revolutionizing the joint-health segment.

Suanfarma - a specialised supplier of raw materials to the pharmaceutical industry - acquires a stake in the CDMO.

Will provide cGMP storage, local labelling, secondary packaging, comparator sourcing, handling and distribution of ambient and cold chain supplies to clinical site returns management.

Patent covers East Indian sandalwood oil-containing compositions that can be used to treat a variety of cancers.

The CDMO' investment will reinforce its expertise in opiate and synthetic drug development and production.

Is the first registration Dechra has achieved through Putney's development pipeline since it acquired the US-based business

Company has invested in semi-automated vacuum stopper equipment to generate prefilled syringe samples that can be used to screen and select components, complete compatibility studies, and conduct developmental stability studies.

Designation also includes the associated interstitial lung disease.

“The Clear Your Head Medicine” is poised to lead the sinus category, offering clarity in a confusing allergy and cold aisle.

UK has approved a new drug product for Glaucoma diseases, delivered with Novelia®, Nemera’s multidose preservative-free eyedropper. The Novelia® system is the first and only preservative-free multidose eyedropper UK-approved for a glaucoma drug

Chrono Therapeutics is developing a wearable transdermal drug delivery device offering a personalised behavioural support system that times nicotine delivery to when smokers have their strongest cravings.

Enhances viral safety while maintaining cell line productivity, protein quality.

Patent claims are directed to a novel formulation of Locilex, a topical antimicrobial peptide formulated as a topical cream, and the use of Locilex as a method of treating skin or wound infections.

Benralizumab Phase III trials met primary and key secondary endpoints.

The acquisition will generate a new and strong international microbial CMO, offering the complete services from process development to large-scale market supply.

Company's immuno-oncology and histology services have allowed clients' go/no-go decisions to be made earlier in the drug development process and ultimately reduce clinical attrition.

Patent and market authorization for human hyperacute serum product.

The BlueWind VIVENDI System is a wireless, battery-less neurostimulator which is 90% smaller than typical neurostimulators in the market.

The Aerobika device demonstrated a clinically-significant reduction in exacerbations in as little as 30 days of treatment, when used as an add-on to usual COPD medications.

To be Commercialized in Portugal and Ireland as Vitaros and in Poland as Vytaros.

The leading global producer of calcium carbonate sets up a state-of-the-art laboratory for pharmaceutical and nutraceutical applications.

Officially opened on 15th March 2016, Omya’s new pharmaceutical and nutraceutical laboratory ...

2016 report topics include 3D printing, FDA quality metrics, contract services, pharma growth in China and India, and generic licensing.

The plant will continue to manufacture critical AstraZeneca pharmaceutical products on a contract basis.

Webinar will focus on the nasal drug delivery route in the treatment of central nervous system diseases.

The investment includes the installation of new multi-purpose reactors and upgrading of the control room within an existing plant on site.

Acquisition of RetroSense Therapeutics adds global rights to RST-001, a novel gene therapy approach for the potential treatment of Retinitis Pigmentosa.

Ultibro Breezhaler reduced rate of all COPD exacerbations across different patient sub-groups vs Seretide in new analyses from FLAME study.

Tiotropium+olodaterol Respimat along with exercise training and behavior modification significantly increased exercise capacity compared to placebo.

A range of best-in-class solutions that drive productivity in the laboratory.

First Generic and clinically validated product for Multiple Sclerosis in Europe.

Increased risk of stroke fails to support further development.

Generic equivalents to Razadyne.

Compact device capable of delivering high viscosity drugs including some of the newest biologics.

Therapeutic equivalent generic version of GSK's Wellbutrin SR.

US Patent and Trademark Office has ruled in favour of Mylan in its inter partes review proceeding.

Company also provides update on new interim analysis from Phase Ib study.

Unique product and service portfolio extensively covers all steps from cell line development to commercial manufacturing processes.

The CDMO has expanded its capabilities with a new automatic vial filling line to meet increased demand.

The artificial nose can sniff out Pulmonary Arterial Hypertension on a person’s breath as the disease alters its signature.

The new facility will be the global Center of Excellence for Extractable Studies and Impurities Profiling, as a hub across the global network of laboratories.

Company will discuss common tabletting problems such as increasing output without capital expenditure, eliminating sticking and abrasion, minimising headwear and corrosion, all of which can be done through innovative means.

The agreement comprises technology transfer and commercial manufacturing of the products Entocort and Asacol.